EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report

Toshiharu Tsutsui iD, Koki Hata, Makoto Kawaguchi, Hiroaki Kobayashi, Yumiko Kakizaki, Yoshihiro Miyashita iD

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15015 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Toshiharu Tsutsui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Kofu-shi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Immunological, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine release syndrome (CRS) is a severe and life‐threatening toxicity typically reported in chimeric antigen receptor T cell therapy and is rarely reported in immune checkpoint inhibitor (ICI) therapy. This study reports the case of a 75‐year‐old Japanese woman who received nivolumab plus ipilimumab therapy for the postoperative recurrence of non‐small cell lung cancer. She was admitted to our hospital with fever, hypotension, hepatic disorder, and thrombocytopenia. We observed slight skin rashes on her neck on admission, which spread rapidly across her body within a few days. We diagnosed CRS complicated by severe rashes. CRS symptoms were resolved with corticosteroid therapy, and did not recur thereafter. CRS is a rare, but important, immune‐related adverse event associated with ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntineoplastic Agents, ImmunologicalLung NeoplasmsFemaleHumansAgedNivolumabIpilimumabCytokine Release Syndrome

Stichwörter der Autor:innen

cytokine release syndromeimmune checkpoint inhibitorsimmune-related adverse events

Substanzen

NivolumabIpilimumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Lung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Kofu-shi, Japan.

ORCID-Profile: Toshiharu Tsutsui, Yoshihiro Miyashita

Zitieren

APA

Tsutsui, T., Hata, K., Kawaguchi, M., Kobayashi, H., Kakizaki, Y., & Miyashita, Y. (2023). Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15015

Vancouver

Tsutsui T, Hata K, Kawaguchi M, Kobayashi H, Kakizaki Y, Miyashita Y. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15015

BibTeX
@article{Tsutsui2023,
  author = {Tsutsui, Toshiharu and Hata, Koki and Kawaguchi, Makoto and Kobayashi, Hiroaki and Kakizaki, Yumiko and Miyashita, Yoshihiro},
  title = {Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15015}
}
Kostenlos starten →